相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF
Jaclyn F. Hechtman et al.
MOLECULAR CANCER RESEARCH (2016)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Evgeny Yakirevich et al.
CLINICAL CANCER RESEARCH (2016)
Identification of neutral tumor evolution across cancer types
Marc J. Williams et al.
NATURE GENETICS (2016)
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
Andrew Rankin et al.
ONCOLOGIST (2016)
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Roberto Moretto et al.
ONCOLOGIST (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
Alessio Amatu et al.
BRITISH JOURNAL OF CANCER (2015)
Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
Laurent Creancier et al.
CANCER LETTERS (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Enzo Medico et al.
NATURE COMMUNICATIONS (2015)
Identification and characterization of RET fusions in advanced colorectal cancer
Anne-France Le Rolle et al.
ONCOTARGET (2015)
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
Jeeyun Lee et al.
ONCOTARGET (2015)
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line
Su Jin Lee et al.
ONCOTARGET (2015)
ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma
Michelle Houang et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
Mihaela Angelova et al.
GENOME BIOLOGY (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
Dara L. Aisner et al.
MOLECULAR CANCER RESEARCH (2014)
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini et al.
MOLECULAR ONCOLOGY (2014)
RNF43 is frequently mutated in colorectal and endometrial cancers
Marios Giannakis et al.
NATURE GENETICS (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Tyrosine kinase gene rearrangements in epithelial malignancies
Alice T. Shaw et al.
NATURE REVIEWS CANCER (2013)
Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
Mai Yamauchi et al.
GUT (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
Eva Lin et al.
MOLECULAR CANCER RESEARCH (2009)
分享论文
